P
P

Pfizer


Notícias

New York Times business news - May 27

May 27 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - Carl Icahn gets only 1 percent of McDonald's MCD.N investors to support his campaign on pigs, the activist investor had nominated two directors to the company’s board as part of
B
P

New York Times business news - May 24

May 24 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - JPMorgan Chase & Co JPM.N expects to make money from rising interest rates and bumpy markets, market volatility will increase revenue from trading, while borrowers will be shellin
J
P
S

Wall Street rallies to higher close boosted by banks, big tech

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) (Updates to closing bell) By Stephen Culp NEW YORK, May 23 (Reuters) - U.S. stocks ended higher on Monday as gains from banks and a rebound in megacap market leaders supported a broad-based rally following Wall Street's longest streak of wee
A
B
J
M
P
U
U

Wall Street rebounds with assist from banks, big tech

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * JPMorgan leads banks higher on upbeat interest income outlook * Broadcom shares fall on potential VMware buyout * Indexes up: Dow 1.98%, S&P 1.73%, Nasdaq 1.26% By Stephen Culp NEW YORK, May 23 (Reuters) - Wall Street rallied on Monday as
A
B
J
P
U
U

U.S. FDA sets June meeting dates for Moderna, Pfizer small children 19 vaccines

WASHINGTON, May 23 (Reuters) - The U.S. Food and Drug Administration set June 14-15 as the new meeting date to review Moderna Inc's emergency authorization request for its COVID-19 vaccine for children aged 6 months to 5 years and Pfizer Inc's vaccine for those aged 6 months through 4 years. The new dates for our pediatric COVID-19 vaccine advisory
P

Wall Street ends mixed after punishing week

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * Ross Stores plunges after cutting 2022 forecast * S&P 500 +0.01%, Nasdaq -0.30%, Dow +0.03% (Updates with details at end of session) By Noel Randewich and Amruta Khandekar May 20 (Reuters) - Wall Street ended mixed on Friday after a volati
G
N
P
T
R
U
U

Switzerland buys Pfizer's 19 antiviral Paxlovid

BERLIN, May 20 (Reuters) - Switzerland signed a contract to buy Pfizer's anti-viral drug Paxlovid to treat Covid-19, it said on Friday. The European country said it had signed a contract to buy 12,000 packages and first treatments for certain at-risk patients would start this month. Reporting by Kirsti Knolle, Editing by Miranda Murray
P

British Business - May 11

May 11 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Tesla Inc's TSLA.O factory in Shanghai has scaled back production after being hit by supply chain problems, only three weeks after work restarted there. Link - Pf
P
T
T
E

Evonik to invest 8 bln eur by 2030 in high-margin businesses -CEO

* Around 4 bln eur to be invested in Germany * Russia business to come to a standstill * Baby business, C4 unit, Luelsdorf site up for sale BERLIN, May 10 (Reuters) - German chemicals company Evonik EVKn.DE plans to invest 8 billion euros ($8.45 billion) by 2030 to boost growth in its smart materials, specialty additives and nutrition & care units,
P
V

BioNTech's Q1 vaccine sales triple but it still flags full-year decline

FRANKFURT, May 9 (Reuters) - BioNTech's 22UAy.DE first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer PFE.N , but the German biotech firm is still forecasting a full-year decline in vaccine sales. Quarterly revenues more than tripled from a year earlier to 6.37 billion euros ($6.73 bi
P

BioNTech posts tripled Q1 vaccine sales but still flags full-year decline

FRANKFURT, May 9 (Reuters) - BioNTech 22UAy.DE said first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer PFE.N , but the German biotech firm reaffirmed its forecast for a full-year decline in vaccine sales. First-quarter revenues more than tripled from the year-earlier period, to 6.37
P

EU regulator hopes to approve COVID variant-adapted vaccines by autumn

May 5 (Reuters) - The European Union's drug regulator said on Thursday it hoped to have vaccines adapted to address coronavirus variants, such as Omicron, approved by September. "Our priority is to ensure that adaptive vaccines are possibly approved by September at the latest to be ready for the rollout of new immunisation campaigns in the EU in th
P

Wall St Week Ahead-Rocky stock market faces Fed test with eyes on tightening plans

By Lewis Krauskopf NEW YORK, April 29 (Reuters) - A volatile stock market faces a critical test next week, when the U.S. Federal Reserve is expected to raise interest rates and give more insight on its plans for tightening monetary policy to fight surging inflation. Worries over an increasingly hawkish Fed have helped drag the benchmark S&P 500 ind
P
S
U

Wall St Week Ahead-Rocky stock market faces Fed test with eyes on tightening plans

(Updates with further market data) By Lewis Krauskopf NEW YORK, April 29 (Reuters) - A volatile stock market faces a critical test next week, when the U.S. Federal Reserve is expected to raise interest rates and give more insight on its plans for tightening monetary policy to fight surging inflation. Worries over an increasingly hawkish Fed have he
A
P
S
U

Wall St Week Ahead-Rocky stock market faces Fed test with eyes on tightening plans

By Lewis Krauskopf NEW YORK, April 29 (Reuters) - A volatile stock market faces a critical test next week, when the U.S. Federal Reserve is expected to raise interest rates and give more insight on its plans for tightening monetary policy to fight surging inflation. Worries over an increasingly hawkish Fed have helped drag the benchmark S&P 500 ind
P
S
U

Wall Street Journal - April 27

April 27 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - U.S. Vice President Kamala Harris tested positive for COVID-19 on Tuesday, her press secretary, Kirsten Allen, said. on.wsj.com/3EP4CCf - Mattel Inc MAT.O has held talks with private-equi
M
P

India to face more power cuts due to coal shortage, soaring demand

* India FY23 power output seen 15.2% up, coal-fired power over 17% Coal trains to utilities from April 1-6 at 379/day vs 453 needed Coal India FY23 supply target to power sector 565 mln T * Total FY23 local coal requirement at 760 mln T By Sudarshan Varadhan CHENNAI, April 12 (Reuters) - India is likely to face more power cuts this year as utilitie
P

India to face more power cuts due to coal shortage, soaring demand

* India FY23 power output seen 15.2% up, coal-fired power over 17% Coal trains to utilities from April 1-6 at 379/day vs 453 needed Coal India FY23 supply target to power sector 565 mln T * Total FY23 local coal requirement at 760 mln T By Sudarshan Varadhan CHENNAI, April 12 (Reuters) - India is likely to face more power cuts this year as utilitie
P

UK Stocks-Factors to watch on April 12

April 12 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Tuesday, with futures FFIc1 down 0.59%. * EASYJET: Britain's easyJet EZJ.L said it had outperformed its first-half expectations despite the challenges of COVID-19 and rising fuel prices, with capacity ramping up to reach 80% of pre-pandemic levels in March and a recovery i
E
M
P
P
P
U
P

UK Stocks-Factors to watch on April 12

April 12 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Tuesday, with futures FFIc1 down 0.78%. * PARKER-HANNIFIN-MEGGITT: U.S. engineering and aerospace group Parker-Hannifin PH.N on Monday won EU antitrust approval for its 6.3-billion-pound ($8.2 billion) planned acquisition of Britain's Meggitt MGGT.L after pledging to sell
E
M
P
P
U
P



Condições

Ativos populares

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Usamos cookies para lhe dar a melhor experiência no nosso website. Ler mais ou alterar as configurações de cookies.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.